Enumeral Biomedical Holdings Inc fka ENUMQ

[undtrdr]

The one time I did several months ago (Kevin Sarney handles IR) he was short & to the point referring me to filings/Pr's keeping cards held closely to their chest as one would expect.
They don't reveal much just yet even at conferences and the pps, albeit a bargain, may be stuck in this range for some time yet, but eventually we will hear more big player collaborations.

From the website:

We are leveraging the breadth of our technology through strategic collaborations. To date, we have engaged in several proof-of-concept collaborations with several leading pharmaceutical companies. Through them, our technology has been validated in a commercial setting, and a number of applications have been demonstrated.

In the meantime Dr. Tinkelenberg can conjure up cash at will, it is his expertise for over a decade for bio's ... and my bet is whatever form it takes it will be non-dilutive considering the appetite for next generation check point inhibitors

Arthur H. Tinkelenberg, Ph.D.

President, Chief Executive Officer, Director and Co-Founder

Arthur has been President, Chief Executive Officer and a director since 2010. He has broad experience in the business and finance of healthcare enterprises and basic life sciences research. Prior to joining Enumeral, he was a partner in Ascent Biomedical Ventures, a life sciences venture capital firm focused on early-stage biomedical technologies, where he was responsible for originating and managing numerous biotechnology and medical device company investments from 2003 through 2009. Prior to venture capital, he served in the healthcare corporate finance and mergers and acquisitions group of Robertson Stephens. Before industry, he conducted research in lipid metabolism, genomics and cell biology as a Research Scientist at Columbia University from 1996 through 2000. He is a published author and inventor on a number of patents. He received his Ph.D. in molecular genetics from the Rockefeller University and his B.A. in biology from Grinnell College.

We are leveraging the breadth of our technology through strategic collaborations. To date, we have engaged in several proof-of-concept collaborations with several leading pharmaceutical companies. Through them, our technology has been validated in a commercial setting, and a number of applications have been demonstrated.